Nano-based strategies to overcome p-glycoprotein-mediated drug resistance. 2016

Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
a Student Research Committee, Faculty of Advanced Medical Sciences and Research Center for Pharmaceutical Nanotechnology , Tabriz University of Medical Sciences , Tabriz , Iran.

BACKGROUND The discussion about cancer treatment has a long history. Chemotherapy, one of the promising approaches in cancer therapy, is limited in the clinic as plenty of factors evolve and prevent appropriate therapeutic response to drugs. Multi-drug resistance (MDR), which is mostly P-glycoprotein-mediated, is described as the most well-known impediment in this contribution. It extrudes several agents out of cells, arising MDR and decreasing the bioavailability of drugs. Hence, cancer cells become insensitive to chemotherapy. METHODS Many agents have been developed to reverse MDR, but it is difficult to deliver them into cancer sites and cancer cells. The emerging nano-based drug delivery systems have been more effective to overcome P-glycoprotein-mediated MDR by increasing the intracellular delivery of these agents. Here, we represent systems including siRNA-targeted inhibition of P-gp, monoclonal antibodies, natural extracts, conventional inhibitors, hard nanoparticles and soft nanoparticles as delivery systems in addition to a novel approach applying cell penetrating peptides. CONCLUSIONS Overcoming cancer drug resistance using innovative nanotechnology is being increasingly used and developed. Among resistance mechanisms, drug efflux transporter inhibitors and MDR gene expression silencing are among the those being investigated. In the near future, it seems some of these nanomedical approaches might become the mainstay of effective treatment of important human conditions like cancer.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D053758 Nanoparticles Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging. Nanocrystalline Materials,Nanocrystals,Material, Nanocrystalline,Materials, Nanocrystalline,Nanocrystal,Nanocrystalline Material,Nanoparticle
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D020168 ATP Binding Cassette Transporter, Subfamily B, Member 1 A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE). ATP-Dependent Translocase ABCB1,MDR1 Protein,MDR1B Protein,Multidrug Resistance Protein 1,P-Glycoprotein,P-Glycoprotein 1,ABCB1 Protein,ATP Binding Cassette Transporter, Sub-Family B, Member 1,ATP-Binding Cassette, Sub-Family B, Member 1,CD243 Antigen,PGY-1 Protein,1, P-Glycoprotein,ABCB1, ATP-Dependent Translocase,ATP Dependent Translocase ABCB1,Antigen, CD243,P Glycoprotein,P Glycoprotein 1,PGY 1 Protein,Protein, MDR1B,Translocase ABCB1, ATP-Dependent
D020868 Gene Silencing Interruption or suppression of the expression of a gene at transcriptional or translational levels. Gene Inactivation,Inactivation, Gene,Silencing, Gene

Related Publications

Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
January 2008, Current medicinal chemistry,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
January 2021, Nature communications,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
February 2022, Nanomedicine : nanotechnology, biology, and medicine,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
January 2007, Molecular pharmaceutics,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
November 2001, Pharmacogenomics,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
November 2004, International journal of clinical pharmacology and therapeutics,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
December 2004, Leukemia,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
December 2018, Molecular cancer therapeutics,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
October 2021, Cancers,
Mehri Niazi, and Parvin Zakeri-Milani, and Saeedeh Najafi Hajivar, and Mehdi Soleymani Goloujeh, and Nasrin Ghobakhlou, and Javid Shahbazi Mojarrad, and Hadi Valizadeh
December 2001, British journal of cancer,
Copied contents to your clipboard!